Product Description
Clindamycin is a medication used for the treatment of numerous infections, including but not limited to septicemia, intra-abdominal infections, lower respiratory infections, gynecological infections, bone and joint infections, and skin and skin structure infections. Clindamycin is also used in the treatment of streptococcal pharyngitis, acne vulgaris, bacterial vaginosis, and severe pelvic inflammatory disease. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK519574/)
Mechanisms of Action: Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Acne Vulgaris | Acne Vulgaris | Vaginosis, Bacterial | Acne Vulgaris
Known Adverse Events: Pain Unspecified | Erythema | Nasopharyngitis | Pharyngitis | Sinusitis | Candidiasis | Candidiasis, Vulvovaginal | Sunburn | Pruritus
Company: Stiefel
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Acne Vulgaris
Phase 2: Infertility
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 23-01/ClindaTret-G | P3 |
Unknown Status |
Unknown |
2026-05-06 |
|
| ABCG-2407 | P1 |
Completed |
Acne Vulgaris |
2024-09-03 |
|
| 2022-003070-23 | P3 |
Active, not recruiting |
Acne Vulgaris |
2024-01-20 |
|
| 2016-002385-31 | P2 |
Active, not recruiting |
Infertility |
2020-02-28 |